A major goal was to design a promoter specific for rhabdomyosarcoma cells over myogenic cells, and while we increased rhabdomyosarcoma specificity with our ∆MEF3/NF1 MYOGENIN promoter, there remains residual toxicity in myoblasts. The gene discussed is MYOG; the disease is rhabdomyosarcoma.